MDBIF (TrivarX) Research & Development: $0.01 Mil (TTM As of Dec. 2025)


What is TrivarX Research & Development?

TrivarX MDBIF Research & Development is $0.01 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TrivarX's Research & Development for the six months ended in Dec. 2025 was $0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01 Mil.

TrivarX  (OTCPK:MDBIF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TrivarX Research & Development Related Terms

TrivarX Research & Development Historical Data

* Premium members only.

The historical data trend for TrivarX's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TrivarX Research & Development Chart

TrivarX Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.56 0.21 0.01 0.02

TrivarX Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.01 0.01

TrivarX Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.01 Mil mean?
TrivarX (MDBIF) has a Research & Development of $0.01 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on TrivarX and its competitors.
Is TrivarX's Research & Development too high?
TrivarX's current Research & Development is $0.01 Mil.
How does TrivarX's Research & Development compare to VEEV and BTSG?
TrivarX's Research & Development of $0.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TrivarX and its competitors. TrivarX's current Research & Development is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TrivarX stock overvalued right now?
Based on GuruFocus' analysis, TrivarX (MDBIF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.05, compared to a current price of $0.00 — trading 94.8% below its estimated fair value. The current Research & Development is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TrivarX (MDBIF), the current Research & Development is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TrivarX Business Description

Other Exchanges TRI:Australia
Address 647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability. The Company has one operating segment, being the research, development and commercialisation of its software asaService product, and two geographical locations, being Australia and the United States.